Your browser is no longer supported. Please, upgrade your browser.
Xencor, Inc.
Index- P/E91.31 EPS (ttm)0.37 Insider Own0.20% Shs Outstand58.25M Perf Week1.98%
Market Cap1.96B Forward P/E- EPS next Y-2.34 Insider Trans0.00% Shs Float57.44M Perf Month2.99%
Income23.50M PEG- EPS next Q-0.60 Inst Own- Short Float4.60% Perf Quarter-9.77%
Sales178.60M P/S10.96 EPS this Y-363.60% Inst Trans-1.02% Short Ratio12.54 Perf Half Y-25.00%
Book/sh11.11 P/B3.01 EPS next Y-165.90% ROA3.40% Target Price53.55 Perf Year-19.43%
Cash/sh7.68 P/C4.35 EPS next 5Y- ROE4.00% 52W Range30.12 - 58.35 Perf YTD-23.40%
Dividend- P/FCF- EPS past 5Y-21.90% ROI-13.40% 52W High-42.72% Beta0.71
Dividend %- Quick Ratio10.50 Sales past 5Y34.60% Gross Margin- 52W Low10.96% ATR1.18
Employees202 Current Ratio10.50 Sales Q/Q414.50% Oper. Margin-20.70% RSI (14)52.97 Volatility3.57% 3.86%
OptionableYes Debt/Eq0.00 EPS Q/Q241.10% Profit Margin13.20% Rel Volume0.78 Prev Close33.36
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout0.00% Avg Volume210.50K Price33.42
Recom1.80 SMA201.32% SMA502.77% SMA200-17.67% Volume164,335 Change0.18%
Feb-24-21Upgrade Raymond James Mkt Perform → Outperform $58
Mar-04-20Initiated Barclays Underweight $28
Feb-25-20Upgrade Guggenheim Neutral → Buy $43
Jan-30-20Initiated RBC Capital Mkts Outperform $44
Nov-20-19Resumed Guggenheim Neutral
Aug-07-19Downgrade Raymond James Outperform → Mkt Perform
Aug-07-19Downgrade Guggenheim Buy → Neutral
Jun-13-19Initiated Mizuho Buy
Apr-12-19Initiated Guggenheim Buy
Mar-27-19Initiated Berenberg Buy $45
Mar-15-19Initiated Raymond James Outperform
Sep-10-18Resumed BTIG Research Buy $56
Mar-28-18Resumed Leerink Partners Outperform $36
Mar-02-17Reiterated Wedbush Outperform $27 → $33
Mar-02-17Initiated Instinet Neutral $21
Oct-04-16Initiated Piper Jaffray Overweight
Dec-22-15Initiated Canaccord Genuity Buy $20
Aug-05-15Reiterated MLV & Co Buy $22 → $29
Feb-12-15Reiterated Oppenheimer Outperform $22 → $28
Jan-28-15Reiterated MLV & Co Buy $18 → $22
Aug-04-21 11:31PM  
Aug-02-21 04:01PM  
Jul-28-21 04:01PM  
Jul-27-21 05:48PM  
Jul-01-21 10:25AM  
Jun-30-21 09:08AM  
Jun-22-21 06:46AM  
Jun-10-21 03:53PM  
Jun-01-21 05:18AM  
May-27-21 04:01PM  
May-26-21 07:46PM  
May-25-21 11:14AM  
May-12-21 04:01PM  
May-06-21 02:00PM  
May-05-21 05:25PM  
Apr-28-21 04:01PM  
Apr-12-21 12:23PM  
Apr-10-21 08:30AM  
Mar-23-21 04:00AM  
Mar-10-21 08:15PM  
Mar-03-21 04:01PM  
Feb-25-21 08:08AM  
Feb-24-21 12:01AM  
Feb-23-21 04:22PM  
Feb-16-21 04:01PM  
Feb-12-21 08:28AM  
Feb-04-21 04:01PM  
Jan-07-21 08:45AM  
Jan-06-21 04:01PM  
Dec-16-20 10:21PM  
Dec-07-20 08:01AM  
Dec-06-20 05:00PM  
Nov-12-20 04:01PM  
Nov-11-20 04:02PM  
Nov-10-20 07:51AM  
Nov-09-20 08:00AM  
Nov-06-20 03:30PM  
Nov-05-20 05:45PM  
Nov-04-20 10:15AM  
Oct-29-20 04:01PM  
Oct-14-20 05:00PM  
Oct-13-20 12:03PM  
Oct-02-20 09:00AM  
Sep-23-20 12:09PM  
Sep-09-20 04:01PM  
Sep-03-20 08:01AM  
Aug-05-20 04:01PM  
Aug-04-20 05:25PM  
Jul-31-20 10:49PM  
Jul-28-20 05:01PM  
Jul-14-20 11:14AM  
Jul-08-20 08:01AM  
Jun-30-20 11:35PM  
Jun-22-20 09:06AM  
Jun-08-20 01:48PM  
May-26-20 04:01PM  
May-15-20 12:01AM  
May-13-20 05:00PM  
May-11-20 01:35PM  
May-08-20 09:30PM  
May-07-20 04:01PM  
Apr-30-20 04:01PM  
Apr-13-20 03:49PM  
Apr-07-20 02:10PM  
Mar-26-20 08:23AM  
Mar-25-20 04:01PM  
Mar-02-20 02:55PM  
Feb-28-20 07:43AM  
Feb-26-20 11:59AM  
Feb-24-20 05:45PM  
Feb-18-20 08:01AM  
Feb-17-20 12:30PM  
Feb-06-20 04:01PM  
Feb-05-20 10:28AM  
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestle S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Desjarlais John RSR. VICE PRESIDENT & CSOMar 03Sale45.031,16552,45491,788Mar 03 08:01 PM
Eckert CeliaVP, GENERAL COUNSELMar 03Sale44.9444419,9553,496Mar 03 08:01 PM
Kuch John JSR. VICE PRESIDENT & CFOMar 03Sale45.0980536,29385,415Mar 03 08:00 PM
Dahiyat Bassil IPRESIDENT & CEOMar 03Sale44.882,850127,909141,064Mar 03 08:01 PM
Kuch John JSR. VICE PRESIDENT & CFOMar 01Option Exercise11.0515,065166,468101,285Mar 03 08:00 PM
Kuch John JSR. VICE PRESIDENT & CFOMar 01Sale48.9015,065736,67286,220Mar 03 08:00 PM
Yang AllenSR. VICE PRESIDENT & CMODec 17Sale43.853,777165,62128,395Dec 18 12:19 PM